Description
Spike S1 (B.1.617 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay Kit | 78288 | Gentaur US, UK & Europe Disrtribition
Category: Coronavirus/Assay Kit
Application: This kit is useful for screening for inhibitors of the interaction between SARS-CoV-2 Spike S1 (B.1.617) and human ACE2.
Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Variant B.1.617, was originally discovered in India. This variant was the precursor to the B.1.617.1 (Kappa) variant and the B.1.617.2 (Delta) variant. It contains mutations L452R, E484Q, D614G and P681R.
Description: The Spike S1 (B.1.617 Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.617) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
Product Type: Assay Kit
Shippement Condition: -80°C
